LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Axsome Therapeutics Inc

Closed

SectorHealthcare

111.62 0.97

Overview

Share price change

24h

Current

Min

110.18

Max

112.63

Key metrics

By Trading Economics

Income

15M

-59M

Sales

2.7M

121M

EPS

-1.216

Profit margin

-48.914

Employees

712

EBITDA

14M

-57M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+64.93% upside

Dividends

By Dow Jones

Next Earnings

4 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-171M

5.3B

Previous open

110.65

Previous close

111.62

News Sentiment

By Acuity

54%

46%

325 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Axsome Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

5 Jun 2025, 20:45 UTC

Earnings

Broadcom 2Q Sales Climb on Booming AI Demand

5 Jun 2025, 23:45 UTC

Market Talk

Nikkei May Decline as Caution Over U.S. Economy Continues -- Market Talk

5 Jun 2025, 23:44 UTC

Market Talk

Gold Edges Higher on Weak U.S. Data -- Market Talk

5 Jun 2025, 23:30 UTC

Market Talk

NZME Cost Cuts Can Cushion Effect of Weak Market -- Market Talk

5 Jun 2025, 21:32 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 Jun 2025, 20:45 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:24 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Cont Ops EPS $1.03 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Rev $15B >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Net $4.97B >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Adj EPS $1.58 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q EPS $1.03 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom Sees 3Q Rev $15.8B >AVGO

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: Transaction Is Expected to Close in the 4Q >CEG

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: Calpine Deal Clears Texas Regulatory Review

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: With Approval From PUCT Secured, Transaction Awaits Clearance From NY State Public Service Commission, Federal Energy Regulatory Commission and DOJ >CEG

5 Jun 2025, 19:22 UTC

Market Talk

Oil Futures Resume Upward Moves -- Market Talk

5 Jun 2025, 19:00 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

5 Jun 2025, 18:32 UTC

Market Talk

Gold Slips After Trump-Xi Call -- Market Talk

5 Jun 2025, 18:26 UTC

Earnings

These Stocks Are Moving the Most Today: Broadcom, Tesla, Circle, Brown-Forman, MongoDB, Planet Labs, ChargePoint, Ciena, and More -- Barrons.com

5 Jun 2025, 18:06 UTC

Market Talk

Transpacific Ship Freight Rates Spike on China Tariff Truce -- Market Talk

5 Jun 2025, 16:30 UTC

Acquisitions, Mergers, Takeovers

Vallourec Completes The Acquisition Of Thermotite Do Brasil >VK.FR

5 Jun 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 Jun 2025, 16:18 UTC

Market Talk

U.S. Natural Gas Market Shrugs Off Big Storage Build -- Market Talk

5 Jun 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 Jun 2025, 16:12 UTC

Market Talk

Global Energy Roundup: Market Talk

5 Jun 2025, 16:12 UTC

Market Talk

Copper Prices Rise on Positive Signals From Trump on China Trade Talks -- Market Talk

5 Jun 2025, 16:03 UTC

Market Talk

U.S. Diesel, Gasoline Futures Pick Back Up -- Market Talk

5 Jun 2025, 15:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Axsome Therapeutics Inc Forecast

Price Target

By TipRanks

64.93% upside

12 Months Forecast

Average 178.36 USD  64.93%

High 210 USD

Low 148 USD

Based on 16 Wall Street analysts offering 12 month price targets forAxsome Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

16

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

107.24 / 112.29Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

325 / 380 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.